JP2019518798A - リポヌクレオチドに基づくardsの治療 - Google Patents
リポヌクレオチドに基づくardsの治療 Download PDFInfo
- Publication number
- JP2019518798A JP2019518798A JP2019519626A JP2019519626A JP2019518798A JP 2019518798 A JP2019518798 A JP 2019518798A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019519626 A JP2019519626 A JP 2019519626A JP 2019518798 A JP2019518798 A JP 2019518798A
- Authority
- JP
- Japan
- Prior art keywords
- cdp
- composition
- choline
- ards
- dag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662355096P | 2016-06-27 | 2016-06-27 | |
| US62/355,096 | 2016-06-27 | ||
| PCT/US2017/039545 WO2018005527A1 (en) | 2016-06-27 | 2017-06-27 | Liponucleotide-based therapy for ards |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019518798A true JP2019518798A (ja) | 2019-07-04 |
| JP2019518798A5 JP2019518798A5 (enExample) | 2020-08-06 |
Family
ID=60786443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019519626A Pending JP2019518798A (ja) | 2016-06-27 | 2017-06-27 | リポヌクレオチドに基づくardsの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10874684B2 (enExample) |
| EP (2) | EP3474853A4 (enExample) |
| JP (1) | JP2019518798A (enExample) |
| KR (1) | KR20190022682A (enExample) |
| CN (1) | CN109475554A (enExample) |
| AU (1) | AU2017289278A1 (enExample) |
| CA (1) | CA3029005A1 (enExample) |
| SG (1) | SG11201811595SA (enExample) |
| WO (1) | WO2018005527A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019518798A (ja) * | 2016-06-27 | 2019-07-04 | オハイオ・ステイト・イノベーション・ファウンデーション | リポヌクレオチドに基づくardsの治療 |
| EP3645009A4 (en) * | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
| US20230181509A1 (en) * | 2020-03-31 | 2023-06-15 | Diffusion Pharmaceuticals Llc | The use of diffusion enhancing compounds for treatment of viral and bacterial induced respiratory disease |
| CA3177338A1 (en) * | 2020-05-01 | 2021-11-04 | Marco A. Chacon | Method for treating respiratory viral infections comprising administration of fatty acid compositions |
| US20250177541A1 (en) * | 2022-03-11 | 2025-06-05 | Arizona Board Of Regents On Behalf Of Arizona State University | Pegylated serp-1 protein treatment improves outcomes after sars-cov-2 infection |
| WO2023177995A2 (en) * | 2022-03-18 | 2023-09-21 | Ohio State Innovation Foundation | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| JP2005513023A (ja) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
| JP2008542280A (ja) * | 2005-05-23 | 2008-11-27 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5470838A (en) * | 1987-10-28 | 1995-11-28 | Pro-Neuron, Inc. | Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine |
| KR100290132B1 (ko) * | 1994-07-01 | 2001-05-15 | 마이클 바마트 | 전신 염증 및 염증성 간염 치료용 피리미딘 누클레오티드 전구체 |
| US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
| US20040049022A1 (en) * | 2001-04-24 | 2004-03-11 | Nyce Jonathan W. | Composition & methods for treatment and screening |
| EP2332546A1 (en) * | 2001-07-13 | 2011-06-15 | Paratek Pharmaceuticals, Inc. | Tetracyclines for the treatment of stroke |
| EA012138B1 (ru) * | 2004-11-17 | 2009-08-28 | Йиссум Рисерч Дивелопмент Компани Оф Дзе Хебрю Юниверсити Оф Иерусалим | Применение конъюгатов липидов при лечении заболеваний |
| CN101506218A (zh) * | 2005-05-23 | 2009-08-12 | 麻省理工学院 | 含有多不饱和脂肪酸的组合物及其使用方法 |
| JP2019518798A (ja) * | 2016-06-27 | 2019-07-04 | オハイオ・ステイト・イノベーション・ファウンデーション | リポヌクレオチドに基づくardsの治療 |
| EP3645009A4 (en) * | 2017-06-27 | 2021-03-31 | The Ohio State Innovation Foundation | LIPONUCLEOTIDE THERAPY FOR COPD |
| WO2019005901A1 (en) * | 2017-06-27 | 2019-01-03 | Ohio State Innovation Foundation | Liponucleotide-based therapy for asthma |
-
2017
- 2017-06-27 JP JP2019519626A patent/JP2019518798A/ja active Pending
- 2017-06-27 AU AU2017289278A patent/AU2017289278A1/en not_active Abandoned
- 2017-06-27 CN CN201780039385.4A patent/CN109475554A/zh active Pending
- 2017-06-27 SG SG11201811595SA patent/SG11201811595SA/en unknown
- 2017-06-27 CA CA3029005A patent/CA3029005A1/en active Pending
- 2017-06-27 EP EP17821089.4A patent/EP3474853A4/en not_active Withdrawn
- 2017-06-27 EP EP23207788.3A patent/EP4292651A3/en active Pending
- 2017-06-27 WO PCT/US2017/039545 patent/WO2018005527A1/en not_active Ceased
- 2017-06-27 KR KR1020197002042A patent/KR20190022682A/ko not_active Ceased
-
2018
- 2018-12-21 US US16/230,225 patent/US10874684B2/en active Active
-
2020
- 2020-11-19 US US16/952,557 patent/US20210069225A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4386078A (en) * | 1980-03-03 | 1983-05-31 | The Ohio State University Research Foundation | Therapeutic agents for preventing phospholipid degradation and free fatty acid proliferation |
| JPH02500372A (ja) * | 1987-10-28 | 1990-02-08 | プロ‐ニューロン,インコーポレーテッド | アシル化ウリジンおよびシチジンならびにその使用 |
| US20030181353A1 (en) * | 1998-08-03 | 2003-09-25 | Nyce Jonathan W. | Composition & use as analgesic, anti-inflammatory, wound healing agent, for treatment of heart conditions, assessment of heart function & tissue & cell protection & healing & reperfusion, mood disorders & symptoms & sequelae of menopause & for inducing unconsciousness, sleep & anesthesia |
| JP2005513023A (ja) * | 2001-11-21 | 2005-05-12 | ダンマークス・ヨードブルースフォースクニング | 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用 |
| JP2008542280A (ja) * | 2005-05-23 | 2008-11-27 | マサチューセッツ・インスティチュート・オブ・テクノロジー | Pufa及び/又はウリジンを含有する組成物及びそれを使用した方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3474853A1 (en) | 2019-05-01 |
| WO2018005527A1 (en) | 2018-01-04 |
| SG11201811595SA (en) | 2019-01-30 |
| EP4292651A3 (en) | 2024-03-13 |
| AU2017289278A1 (en) | 2019-01-17 |
| EP4292651A2 (en) | 2023-12-20 |
| US10874684B2 (en) | 2020-12-29 |
| EP3474853A4 (en) | 2020-02-19 |
| US20190134074A1 (en) | 2019-05-09 |
| CA3029005A1 (en) | 2018-01-04 |
| CN109475554A (zh) | 2019-03-15 |
| KR20190022682A (ko) | 2019-03-06 |
| US20210069225A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019518798A (ja) | リポヌクレオチドに基づくardsの治療 | |
| US20240245646A1 (en) | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation | |
| JP2016516773A5 (enExample) | ||
| JP6359583B2 (ja) | 肝細胞がんの予防及び/又は治療のための医薬 | |
| JP2001520656A (ja) | 抗腫瘍剤としてのホルボールエステル類 | |
| CN1681489A (zh) | 增加抗肿瘤活性的化疗药物的联用 | |
| WO2019178023A1 (en) | Methods of Treating or Preventing Acute Respiratory Distress Syndrome | |
| US20170354711A1 (en) | High density lipoprotein nanoparticles for inflammation | |
| CN107137417B (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| TW202203946A (zh) | 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物 | |
| JP2016503035A (ja) | 肝疾患または肝障害の治療のための使用および方法 | |
| JP2013510838A (ja) | 微生物感染症の治療 | |
| HK40003888A (en) | Liponucleotide-based therapy for ards | |
| EP4104825A1 (en) | Pharmaceutical composition for inhibiting inflammatory response comprising hydroxyurea | |
| US20250170246A1 (en) | Cdp-choline a host-directed therapeutic for disease caused by sars cov-2 infection | |
| JP2017527567A5 (enExample) | ||
| Chou et al. | Rapid development of severe skin rash after adding valproic acid in a case of bipolar depression treated with low-dose lamotrigine | |
| CN112533604A (zh) | 用于治疗癌症的组合疗法 | |
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| JP7228895B2 (ja) | 敗血症の予防又は治療用組成物 | |
| JP6959049B2 (ja) | 新規低アルブミン血症改善薬 | |
| JP2019503344A (ja) | 細菌感染を治療する新規方法 | |
| Vigneshwaran et al. | Physiological and haematobiochemical evaluation of tramadol-midazolam-ketamine anaestheisia in geriatric dogs | |
| CN1739543A (zh) | 抗肿瘤化合物nobilisideA单乙酰化物脂质体静脉注射液及其制法 | |
| WO2022121884A1 (zh) | 伊维菌素及其类似物在皮肤相关疾病治疗中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200626 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200626 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210706 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220208 |